Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Credible fact checking can effectively reduce vaccine misinformation on social media

Social media misinformation can negatively influence people's attitudes about vaccine safety and effectiveness, but credible organizations -- such as research universities and health institutions -- can play a pivotal role in debunking myths with simple tags that link to factual information, University of California, Davis, researchers, suggest in a new study.

7 Jan 2021

Proteogenomics can help determine effective treatment for head and neck squamous cell carcinoma

Proteogenomic analysis may offer new insight into matching cancer patients with an effective therapy for their particular cancer.

7 Jan 2021

Potential role of chitinase 3-like-1 in severity of COVID-19

Now, an intriguing preprint research paper on the bioRxiv server reports the identification of an enzyme called chitinase 3-like-1 (CHI3L1) that mediates this age-dependent impact of the virus and could serve as a powerful therapeutic approach in mitigating the severity of COVID-19 in this high-risk group.

7 Jan 2021

Innovative artistic intervention can help reduce fatal health threat to young African children

The fatal threat from diarrhea and pneumonia to young children in the world's poorer countries can be drastically reduced by using traditional performing arts to encourage mothers to provide youngsters with safe food and water, a new study reveals.

7 Jan 2021

San Francisco wrestles with drug approach as death and chaos engulf Tenderloin

In early 2019, Tom Wolf posted a thank-you on Twitter to the cop who had arrested him the previous spring, when he was homeless and strung out in a doorway with 103 tiny bindles of heroin and cocaine in a plastic baggie at his feet.

7 Jan 2021

In Los Angeles and beyond, oxygen is the latest covid bottleneck

As Los Angeles hospitals give record numbers of covid patients oxygen, the systems and equipment needed to deliver the life-sustaining gas are faltering.

7 Jan 2021

Severe COVID-19 recovered patients do not display long-lasting adaptive immune responses, finds study

A team of scientists from the University of Valencia and INCLIVA Health Research Institute, Spain, has recently investigated the durability of immune responses specifically developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).

7 Jan 2021

Study: Durable immunity against secondary COVID-19 disease is possible in most individuals

Researchers who studied antibody and immune cell responses in more than 180 men and women who had recovered from COVID-19 report these patients' immune memory to the virus - across all immune cell types studied - was measurable for up to 8 months after symptoms appeared.

7 Jan 2021

Adaptive immune system against COVID-19 can last for at least eight months

New data suggest that nearly all COVID-19 survivors have the immune cells necessary to fight re-infection.

6 Jan 2021

Is one-dose COVID-19 vaccination better than two?

A recent study published on the preprint server medRxiv in December 2020 reflects on the possibility of using a single-dose vaccine regimen to accomplish large-scale vaccination as early as possible.

6 Jan 2021

Low acceptance of COVID-19 vaccine among healthcare workers in USA

A recent preprint research paper published on the medRxiv server in January 2021 reports that vaccine acceptance is low even among healthcare workers (HCWs) in the USA.

6 Jan 2021

Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection

As a part of the COMMUNITY (COVID-19 Immunity) study, researchers from Sweden reveal long-lasting IgG neutralizing antibody response against spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the vast majority of convalescent individuals – even after asymptomatic or mild infection. Their results are currently available on medRxiv* preprint server.

6 Jan 2021

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that RHB-204 has been granted Fast Track designation by the U.S. Food and Drug Administration for its development as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) - a rare disease for which there is no FDA-approved first-line therapy.

6 Jan 2021

Scientists develop a new method to study the molecular characteristics of T cells

UT Southwestern scientists have developed a new method to study the molecular characteristics of T cells, critical immune cells that recognize and attack invaders in the body such as viruses, bacteria, and cancer.

6 Jan 2021

Smokers at increased risk of developing symptomatic COVID-19

Smoking is associated with an increased risk of COVID-19 symptoms and smokers are more likely to attend hospital than non-smokers, a study has found.

6 Jan 2021

Evidence review: COVID-19 infections are generally 'mild' in children under five years

Babies and asymptomatic cases account for up to half of COVID-19 infections in the under-five age group, which has implications for vaccination programs, a new UNSW study has found.

6 Jan 2021

Researchers claim SARS-CoV-2 B.1.1.7 variant likely to become globally dominant

The new variant of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) detected in England replicates more than two times faster than the earlier strains. This replication advantage promises to make it the dominant global variant very shortly. This finding comes from a startling preprint that appeared on the medRxiv* server in December 2020.

6 Jan 2021

Copper surfaces can inactivate SARS-CoV-2 in as little as one minute, study finds

A new study by researchers at the University of Southampton, UK, has found that SARS-CoV-2 can inactivate on copper surfaces in as little as 1 minute. This is faster than the findings of previous studies in which it took as much as 4 hours before the virus was inactivated.

5 Jan 2021

Researchers develop immunity monitoring to determine the efficacy of COVID-19 vaccine

As the COVID-19 vaccine becomes available to the public, immunity monitoring will play an important role in determining whether the vaccine is effective for an individual, and for how long.

5 Jan 2021

Sugar-binding protein could promote inflammation and worsen sepsis

A sugar-binding protein could fuel terrible inflammation and worsen sepsis, a disease that kills more than 270,000 people every year in the US alone, reports a team of researchers led by UConn Health in the 4 January issue of Nature Immunology.

4 Jan 2021

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Credible fact checking can effectively reduce vaccine misinformation on social media

Proteogenomics can help determine effective treatment for head and neck squamous cell carcinoma

Potential role of chitinase 3-like-1 in severity of COVID-19

Innovative artistic intervention can help reduce fatal health threat to young African children

San Francisco wrestles with drug approach as death and chaos engulf Tenderloin

In Los Angeles and beyond, oxygen is the latest covid bottleneck

Severe COVID-19 recovered patients do not display long-lasting adaptive immune responses, finds study

Study: Durable immunity against secondary COVID-19 disease is possible in most individuals

Adaptive immune system against COVID-19 can last for at least eight months

Is one-dose COVID-19 vaccination better than two?

Low acceptance of COVID-19 vaccine among healthcare workers in USA

Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

Scientists develop a new method to study the molecular characteristics of T cells

Smokers at increased risk of developing symptomatic COVID-19

Evidence review: COVID-19 infections are generally 'mild' in children under five years

Researchers claim SARS-CoV-2 B.1.1.7 variant likely to become globally dominant

Copper surfaces can inactivate SARS-CoV-2 in as little as one minute, study finds

Researchers develop immunity monitoring to determine the efficacy of COVID-19 vaccine

Sugar-binding protein could promote inflammation and worsen sepsis

Innovation in neuroscience drug discovery - eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Innovation in neuroscience drug discovery - eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in